USE OF A NEW FORM OF IBUPROFEN IN CHILDREN WITH FEVER AND ACUTE RESPIRATORY TRACT INFECTIONS
https://doi.org/10.15690/vsp.v12i4.746
Abstract
Aim: to study clinical efficacy, tolerance and safety of a new pelleted ibuprofen form for children in treatment of fever in patients with acute respiratory tract infection. Patients and methods: children aged from 6 to 12 years old with clinical manifestation of respiratory tract infections and requiring antipyretic treatment were included into the study. Children (n = 50) were administered ibuprofen at a single dose of 5–10 mg/kg of body weight, not more than 3–4 times per day. The efficacy assessment included time needed for temperature decrease (assessment was performed in 15, 30 and 60 minutes) and duration of the antipyretic effect (assessment in 6, 8 and 12 hours). Rapidity of analgesic effect in children with ear ache, headache and myalgias was performed in 15, 30, 60 minutes and 6, 8 and 12 hours after the drug intake. Results: antipyretic effect of pelleted ibuprofen for children begins in 15 minutes after its intake. Stable temperature decrease during the first 6 hours was observed in 58% of children (the mean temperature was 37,1 ± 0,3) and maintained up for 12 hours. Relief of pain intensity was established in 62,1% of patients during the first 3 hours, and in 37,9% the pain syndrome was arrested completely. Conclusions: the new pelleted form of ibuprofen for children was proved to have high clinical efficacy and safety in treatment of fever in children with acute respiratory tract infections.
About the Authors
E. E. Lokshina
A.I. Evdokimov Moscow State Medico-Stomatological University
Russian Federation
Russian Federation
S. V. Zaitseva
A.I. Evdokimov Moscow State Medico-Stomatological University
Russian Federation
Russian Federation
O. V. Zaitseva
A.I. Evdokimov Moscow State Medico-Stomatological University
Russian Federation
Zaitseva Ol’ga Vital’evna, Phd, professor, Head of the Department of Pediatrics
Russian Federation
Zaitseva Ol’ga Vital’evna, Phd, professor, Head of the Department of Pediatrics
G. A. Klendar
Central Pediatric Clinical Hospital of FMBA of Russia, Moscow
Russian Federation
Russian Federation
I. G. Stepanova
Central Pediatric Clinical Hospital of FMBA of Russia, Moscow
Russian Federation
Russian Federation
O. N. Misurenko
Central Pediatric Clinical Hospital of FMBA of Russia, Moscow
Russian Federation
Russian Federation
I. N. Selivanova
Central Pediatric Clinical Hospital of FMBA of Russia, Moscow
Russian Federation
Russian Federation
N. V. Shamonina
Central Pediatric Clinical Hospital of FMBA of Russia, Moscow
Russian Federation
Russian Federation
M. S. Kasatkina
Central Pediatric Clinical Hospital of FMBA of Russia, Moscow
Russian Federation
Russian Federation
L. S. Ravshanova
St. Vladimir Pediatric Municipal Clinical Hospital, Moscow
Russian Federation
Russian Federation
References
1. Korovina N. A., Zaplatnikov A. L., Zakharova I. N. Likhoradka u detei. Ratsional'nyi vybor zharoponizhayushchikh lekarstvennykh sredstv [Fever in Children. Sensible Choice of Antifebrile Medicine]. Moscow, 2000. 67 p.
2. Zaitseva O. V. Consilium Medicum — Consilium Medicum. 2007; 1: 21–23.
3. Vetrov V. P., Dlin V. V., Osmanov I. M., Makar'yants M. L., Fisenko V. P. Ratsional'noe primenenie antipiretikov u detei. Pos. dlya vrachei [Sensible Application of Antiseptic Medicine for Children]. Moscow, 2002. 23 p.
4. van den Anker J. N. Optimising the management of fever and pain in children. Int. J. Clin. Pract. Suppl. 2013; 178: 26–32.
5. Chiappini E., Venturini E., Principi N., Longhi R., Tovo P. A., Becherucci P., Bonsignori F., Esposito S., Festini F., Galli L., Lucchesi B., Mugelli A., de Martino M. Update of the 2009 Italian Pediatric Society Guidelines about management of fever in children. Clin. Ther. 2012; 34 (7): 1648–1653.
6. Pereira G. L., Dagostini J. M., Pizzol Tda S. Alternating antipyretics in the treatment of fever in children: a systematic review of randomized clinical trials. J. Pediatr. (Rio J.). 2012; 88 (4): 289–296.
7. Purssell E. Systematic review of studies comparing combined treatment with paracetamol and ibuprofen, with either drug alone. Arch. Dis. Child. 2011; 96 (12): 1175–1179.
8. World Health Organization (WHO). WHO model list of essential medicines for children [updated 2011 Mar]. URL: http://www.who.int/ medicines/publications/essentialmedicines/en
9. Baranov A. A., Tatochenko V. K., Bakradze M. D. Likhoradochnye sindromy u detei: rekomendatsii po diagnostike i lecheniyu [Feverish Syndromes in Children: Guideline on Diagnosis and treatment]. Moscow, Soyuz pediatrov Rossii, 2011. 228 p.
10. Li S. F., Lacher B., Grain E. F. Acetaminophen and ibuprofen dosing by parents. Pediatr. Emerg. Care. 2000; 16: 394–397.
11. Goldman R. D., Ko K., Linett L. J., Solknik D. Antipyretic efficacy and safety of ibuprofen and acetaminophen in children. Ann. Pharmacother. 2004; 38: 146–150. 12. Perrott D. A., Piira T., Goodenough B., Champion D. Efficacy and safety of acetaminophen vs. ibuprofen for treating children's pain or fever: a meta-analysis. Arch. Pediatr. Adolesc. Med. 2004; 158: 521–526.
12. Hay A. D., Costelloe C., Redmond N. M., Montgomery A. A., Fletcher M., Hollinghurst S., Peters T. J. Paracetamol plus ibuprofen for the treatment of fever in children (PITCH): randomised controlled trial. BMJ. 2008; 337: 1302.
13. Lesko S. M., Mitchell A. A. The safety of acetaminophen and ibuprofen among children younger than 2 years old. Pediatrics. 1999; 104: 39.
14. Chandrasekharan N. V., Dai H., Roos K. L., Evanson N. K., Tomsik J., Elton T. S., Simmons D. L. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc. Natl. Acad. Sci. USA. 2002; 99 (21): 13926–13931.
15. Zaitseva O. V. Pediatriya — Pediatrics. 2004; 2: 37–41.
16. Porter J. D., Robinson P. H., Glasgow J. F., Banks J. H., Hall S. M. Trends in the incidence of Reye's syndrome and the use of aspirin. Arch. Dis. Child. 1990; 65: 826–829.
17. Merlani G., Fox M., Oehen H. P., Cathomas G., Renner E. L., Fattinger K., Schneemann M., Kullak-Ublick G. A. Fatal hepatotoxicity secondary to nimesulide. Eur. J. Clin. Pharmacol. 2001; 57: 321–326.
Review
For citations:
Lokshina E.E., Zaitseva S.V., Zaitseva O.V., Klendar G.A., Stepanova I.G., Misurenko O.N., Selivanova I.N., Shamonina N.V., Kasatkina M.S., Ravshanova L.S. USE OF A NEW FORM OF IBUPROFEN IN CHILDREN WITH FEVER AND ACUTE RESPIRATORY TRACT INFECTIONS. Current Pediatrics. 2013;12(4):166-171. (In Russ.) https://doi.org/10.15690/vsp.v12i4.746
Views:
921
Email this article 
